Ich sage es nur EINMAL. ~~~HIV-Test mit Calypte~~~909402~~~ - 500 Beiträge pro Seite

[BulleAndy]

http://www.calypte.com/



Es ist ein MILLIARDEN MARKT

Ticker in Amerika:-CALY-
WKN 909402

Die kommen von 11 USD im Jahr 1997
Top 2000 war 7,5 USD
Aktuell: 0,30 USD (Die Shorty`s haben gut gearbeitet, aber nun sind die LONGS dran )

Gestern sind Sie mir aufgefallen.
70% Plus von 0,25 auf 0,36 ohne Grund
-Da ist etwas im Busch-

MfG
andy

[STOCKLORD]

Heute schon 28% im Minus!!

[BulleAndy]

Scheiß EGAL
Sehe Dir die Chance an und klicke auf die HP



Mein Ziel 4 $
cu
andy

[STOCKLORD]

Naja, dafür das sie Dir erst gestern aufgefallen sind, bist Du aber ganz schön zuversichtlich.
Ich weiss nicht so recht. Könnte aber wirklich was werden.
Allerdings wie´s heute ausschaut sind wir wohl die einzigen, die das glauben.

[morchel]

...täusch ich mich, oder wartet da jemand auf einen Charttechnische Gegenreaktion?

morchel

[BulleAndy]

Die werden steigen.
Glaubt es mir ES IST EINFACH SOOoooooooooooooooooooo
andy

[Siby]

Hallo,
mein lieber Bulli ,

hoooooooooooffentlich ist es so.

Es muß eine Übernahme her ,sonst wird es nichts.

Caly ist fast pleite,verkauft schon das Tfelsilber.

Gruß

[BulleAndy]

Freitag, 1. Juni 2001
Kampf für HIV-Infizierte
Südafrikanischer Aids-Aktivist Nkosi gestorben


Nkosi Johnson (hier mit seiner Pflegemutter Gail) konnte in den letzten Monaten weder essen noch sprechen noch aufrecht sitzen.

Nkosi Johnson ist tot. Der zwölfjährige südafrikanische Junge verlor seinen Kampf gegen Aids. Nkosi starb im Schlaf, wie seine Pflegemutter Gail Johnson mitteilte.

Die letzten Monate hatte Nkosi im Halbkoma verbracht. Seit September vergangenen Jahres konnte er weder essen noch sprechen noch aufrecht sitzen. "Seine Zeit war vorüber, und ich glaube, er wusste das schon seit langem", sagte Johnson unter Tränen. Sie sei unglaublich stolz auf Nkosi, der Junge habe mehr für die Aidskranken in Südafrika getan als jeder andere.

Während seines kurzen Lebens kämpfte Nkosi gegen die Isolierung der HIV-Infizierten in Südafrika. In einer herzzerreißenden Rede zur Eröffnung des Welt-Aids-Kongress in Durban im vergangenen Jahr appellierte der kleine Junge an die Delegierten: "Habt keine Angst vor uns! Wir sind normal, wir haben Hände, wir haben Füße, wir haben Bedürfnisse wie jeder andere. Sorgt für uns und akzeptiert uns!"

Nkosi erreichte, dass aidskranke Kinder in Südafrika heute zur Schule gehen können. Er sammelte Spenden für "Nkosi`s Haven", eine Zufluchtsstätte für HIV-positive Mütter und ihre Kinder in Johannesburg - das alles in einem Land, in dem Aidskranke meist von ihren Familien und der Gesellschaft verstoßen werden.

Als Nkosi am 4. Februar 1989 zur Welt kam, war er bereits mit dem HI-Virus infiziert. Da ihn seine Mutter nicht großziehen konnte, kam Nkosi im Alter von zwei Jahren zu seiner Pflegemutter Johnson. Nkosis Mutter starb 1997 an Aids.

Die Zahl der Aids-Infizierten wird in Südafrika im kommenden Jahrzehnt voraussichtlich von derzeit mehr als vier auf sieben Millionen steigen. An der Immunschwächekrankheit sterben jährlich 2,8 Millionen Menschen. Afrika ist von der Krankheit am stärksten betroffen. Mehr als 70 Prozent der weltweit mit dem AIDS-Virus infizierten Menschen leben auf dem schwarzen Kontinent.

UND wenn ich halt was gutes tue für diese Welt.
Calypte hatte im Dezember folgende NEWS
----------------
Calypte tests used in new testing and treatment strategy in South Africa

Dec 1, 2000—On World AIDS Day, a new joint venture was announced that will help address HIV/AIDS testing and treatment in South Africa. The venture is between Mobile Clinics International, sister company to Calypte`s South African distributor (African Medical Solutions), and two other companies—Lifeworks and the Viral Assistance Centre. (Related story: Calypte Brings HIV Testing to Remote South Africa—Aug 8, 2000

Calypte urine-based HIV antibody tests will be used by the new program to provide cost-effective testing and therapeutic solutions to people working in South African industries. The benefits of Calypte`s urine-based HIV tests make them ideal for this program. Compared to traditional blood-based tests, the Calypte tests are convenient, accurate, and painless. Generally, people are more willing to be tested for HIV when they learn that a blood draw is not necessary.

Recent studies have shown that HIV/AIDS will have a devastating impact on the future economy of South Africa. With morbidity and mortality rates climbing, signs of economic decline are already evident. Employers are experiencing high rates of absenteeism, and disability and death claims are rising. By intervening now in the healthcare of South African workers, the joint venture aims to reduce the negative impact of HIV/AIDS on the South African economy.

The announcement was greeted with enthusiasm by Mr. Tony Leon, leader of the official opposition party, and other leading dignitaries—including members of the Indigenous Rulers of Africa, a society composed of leaders from various South African tribes. The society welcomed the formation of the joint venture on behalf of the majority of black South Africans.

The joint venture has identified large-scale industries (eg, mining and manufacturing) as excellent initial candidates for the program. Clem Sunter, the Chairman of the Chairman`s Fund of Anglo American, the biggest South African mining company, has shown interest in the program and has played an active role in promoting it to the public and to industry representatives. The joint venture will begin testing miners in Rustenberg, Gauteng, in January, 2001.

The South African press covered the joint venture announcement on national television, highlighting the mobile laboratory that Mobile Clinics International uses to test people living in rural South African communities. Mr. Leon`s involvement in the issue was also featured in national and local news stories. The mobile laboratory will be featured in Mining World, South Africa`s premiere mining magazine, in February 2001.

South Africa is one of the nations hardest hit by the HIV/AIDS epidemic. HIV/AIDS statistics from South Africa are extremely alarming: Twenty percent of adult South Africans are HIV-positive, with 2,000 new infections reported each day. Experts predict that by the year 2005, there will be over 6 million people living with HIV in South Africa, and more than 1,600 deaths per day.

Lifeworks is a South African company that helps employers evaluate and address the impact of HIV/AIDS both on employees and on company finances. They have developed the HIV Impact Calculator™ that calculates the consequences HIV may have on a company. Based on their calculations, Lifeworks provides their clients with health management solutions.

The Viral Assistance Centre helps healthcare professionals communicate efficiently and quickly with their patients and colleagues through an Internet-based computer program. Using the program, specialists can advise general care practitioners on the best course of therapy for their HIV/AIDS patients, and communicate data and advice in a cost- and time-efficient manner. The program addresses the shortage of specialist physicians and the poor transportation available in many parts of South Africa.

The founder and chairman of the Viral Assistance Centre, Dr. Willi Sieling, PhD, believes that by using this new program, one doctor will be able to manage up to 20,000 patients at a time. The Viral Assistance Centre also facilitates communication between pharmaceutical companies, distributors, laboratories, etc.

Calypte and its joint venture partners hope that if their solutions have a positive impact in South Africa, they can export their experience to other parts of the world that are also struggling to cope with this devastating epidemic. Watch this space for updates on Calypte`s new ventures in South Africa and around the world.
--------------
Ich hoffe hiermit einen kleinen Beitrag gegen AIDS zu tun.
Calypte ist für die Früherkennung wichtig und die Leute dort haben keine Angst vor den Test
MfG
Andy

[BulleAndy]

Schöner Bericht:
Quelle:http://www.ftor.de/forum/ubbfin1/Forum2/HTML/000754.html
Calypte Biomedical
Der zukünftige Markt von Calypte wächst exponentiell

Der Anstieg von Calypte am heutigen Tage erklärt auf Grund folgender Tatsache:
Calypte Biomedical verkündet heute, daß das Unternehmen eine weitere Finanzierung von seitens privaten Investitionskapitals erhält in Höhe von 25 Mio. US$.
Calypte Biomedical hat seinen Hauptsitz in Alameda/ Kalifornien und ist eine Biotechschmiede, die urinbasierte Diagnoseprodukte herstellt und kommerziell vertreibt. Calypte Biomedical wurde 1988 durch Howard B. Urnovitz gegründet.
Insbesondere finden diese ihren Einsatz beim Check, ob man an einer sexuell übertragbaren Krankheit oder anderer chronischer Krankheit leidet. Insbesondere Aids spielt in der Forschung Calyptes die größte Rolle. Das Unternehmen hat eine eigene Technologie entwickelt, mit Hilfe derer ein Test entwickelt wurde, der das Vorhandensein von HIV-Antikörpern im Urin mit einer Genauigkeit von 99,7% nachweisen kann. Diese Methode ist für den Arzt sicher, da kein Kontakt mit einer evtl. verseuchten Nadel stattfinden kann, äußerst ökonomisch und absolut schmerzfrei für den Patienten. Eines der größten Hindernisse in momentanen HIV-Tests ist, daß viele Leute traditionelle blutbasierende Diagnosetests als schmerzlich oder unangenehm empfinden und sich dadurch auch keiner freiwilligen Prüfung unterziehen.
Das erste Produkt von Calypte ist ein urinbasierter Test. Am 28.5.1998 bewilligte die FDA, daß der Test von Calypte kommerziell genutzt und vertrieben werden durfte. Calypte verkauft seine Produkte momentan in über 40 Ländern schwerpunktmäßig im mittleren Osten, Afrika, Südamerika und Asien mit Hilfe internationaler Verteiler und strategischer Partner. Abnehmer hier sind insbesondere Labors und das Militär.
Calypte besitzt Anteile an Pepgen, einem Unternehmen, welches momentan mit der Entwicklung von zwei Mitteln beschäftigt ist:
ein Antiviren- und Antitumormittel und uteroferrin.
Calypte weist auf momentaner Basis eine Marktkapitalisierung von nur 5,41 US$ auf.
http://www.marketguide.com/mgi/SNAP.asp?nss=www&rt=snap&rn=A…
Calypte Biomedical Corp.
1265 Harbor Bay Parkway
Alameda, CA 94502
Phone: [phone]
Fax: [phone]
--------------------------------------------------------------------------------

Sector: Technology

Industry: Scientific & Technical Instr.

Employees: 65 (12/31/2000)

Market Cap (Mil) $ : 5.41

Complete Financials: Dec 2000


Updated: 05/26/2001

Earnings Announcements:
*Mar 2001
Key Ratios & Statistics
Price & Volume
Recent Price $ 0.21
52 Week High $ 5.13
52 Week Low $ 0.15
Avg Daily Vol (Mil) 0.24
Beta 0.54
Share Related Items
Mkt. Cap. (Mil) $ 5.41
Shares Out (Mil) 25.77
Float (Mil) 19.30
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio (TTM) % 0.00
Financial Strength
Quick Ratio (MRQ) 0.27
Current Ratio (MRQ) 0.79
LT Debt/Equity (MRQ) 0.10
Total Debt/Equity (MRQ) 0.79
Valuation Ratios
Price/Earnings (TTM) NM*
Price/Sales (TTM) 1.46*
Price/Book (MRQ) NM
Price/Cash Flow (TTM) NM
Per Share Data
Earnings (TTM) $ -0.55*
Sales (TTM) $ 0.14*
Book Value (MRQ) $ -0.06
Cash Flow (TTM) $ -0.48
Cash (MRQ) $ 0.03
Mgmt Effectiveness
Return on Equity (TTM) -1,215.19*
Return on Assets (TTM) -180.25
Return on Investment (TTM) -373.20*
Profitability
Gross Margin (TTM) % -78.73
Operating Margin (TTM) % NM
Profit Margin (TTM) % NM*

[BulleAndy]

Quelle:http://www.rethinkingaids.de/afrika/freivon.htm
Ebenfalls im Dezember gab die Weltbank zusammen mit dem IWF und einigen Gläubigerstaaten einen Schuldenerlaß bekannt: Für 22 Länder, unter ihnen viele in Afrika, stehen 42 Milliarden US-$ zur Verfügung, weitere 28 Milliarden US-$ sollen entsprechend vergeben werden. Gekoppelt ist der Erlaß an „Armutsbekämpfung" (der neue Name für die alte Strukturanpassung), deren integraler Bestandteil inzwischen AIDS geworden ist. Das nennt BMZ-Ministerin Wieczorek-Zeul [40] „eine frohe Botschaft für Millionen von Menschen", während es in UNAIDSpeak treffender unter „mainstreaming AIDS" läuft.

[Diagonale]

So, nun reicht`s wieder einmal, Andy überbordet. Hat er den Faden zur Realität vollständig verloren, versucht er alle in seine pseudo-rosarote Welt hineinzuziehen?

Dieser schöne Bericht `Der zukünftige Markt wächst exponentiell` datiert vom 08.11.2000 um 00:28 Uhr.



Die Fakten sprechen klare Worte:

- Cash Flow aus der operativen Geschäftstätigkeit = 0,0
- Eigenkaiptal von ursprünglich $ 46,4 Mio bereits 45,2 Mio. verbraten !

Aeusserste Vorsicht geboten: Andy = Kontraindikator

Gruss
Diagonale

[@andy@spazy@]

[Diagonale]

Ist das dein letzter Klon? Oder hast du noch ein paar auf Lager?

[@andy@spazy@]

EXAKT so fält meine ANTWORT aus



bye

[Diagonale]

Wie immer, es fällt ihm nichts mehr ein; denn Fakten sind Fakten und unwiderlegbar.

Andy, shame on you !!!

[@andy@spazy@]

Dummheit nützt häufiger als sie schadet.
Darum pflegen sich die Allerschlauesten dumm zu stellen.



bye

[BulleAndy]

UND SIE STEIGEN DOCH
So wie TSRG als IHR ALLE mir TSRG ausreden wolltet und dann gingen sie um 700 % nach oben.
cu
andy

[@andy@spazy@]

@Andy

hab ich dir jemals TSRG ausgeredet?

[morchel]

Kauf lieber ADVR!



morchel

[BulleAndy]

morchel die sehen wirklich gut aus
auch deine HP habe ich mir angesehen
HUT AB
wie ist deine erfolgsrate ?
..............................
zu CALY, folgende explosionsgefahr existiert durch das shortselling.
A) caly bekommt von china oder südafrika eine finanzspritze
B) caly bekommt vom staat amerika eine finanzspritze
A) und B) aus humanitären gründen
C) eine übernahme von XYZ

fazit CALY ist hochexplosiv daher auch der shortsqezze vom donnerstag um 70 %
Na klar habe ich drüben billig zugekauft und bin nun gut bestückt für
A-B oder C

[BulleAndy]

Morchel ich zeige Dir mal einen Chart wo man den Boden erkennt.


Die schwarze dünne Linie ist der MACD und er ist logischerweise am Boden nach diesem Kursverfall.
Nun müßte er drehen.
UND denkt dran: KEINER in der USA ließt von Andy den Thread im WOL.
UND auf keinen Fall die MASSE, denn die MASSE macht die Kurse.
MfG
andy

[BulleAndy]

DIE ENTWICKLUNGS-ETAPPEN bei CALY
Market Cap (Mil) $ : 5.41 -PUNKT-
Employees: 65 (12/31/2000) -PUNKT-

http://www.marketguide.com/mgi/signdevt.asp?nss=www&rt=signd…
Calypte Biomedical Corp.
NASD : CALY
Sector: Technology
Industry: Scientific & Technical Instr.


Calypte Biomedical Corp. Sells Minority Stake in Pepgen April 23, 2001
Calypte Biomedical Corp. announced that it has sold its 29% minority position in Pepgen Corporation, a privately held therapeutic company, for $500,000. Calypte`s decision to sell its Pepgen stake reflects the company`s commitment to its core diagnostics business and provides immediate access to cash needed to pay down debt and finance expenditures.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. Announces First Quarter Revenues and Status April 12, 2001
Calypte Biomedical Corp. announced that its preliminary first quarter revenues for the three months ended March 31, 2001 had exceeded its previous best quarter. At the same time, the Company stated that it does not believe that its currently-available financing will be adequate to sustain operations at current levels through the second quarter of 2001. In addition, the Company is currently in discussions with the staff of Nasdaq regarding the Company`s failure to meet the net tangible asset requirement for continued listing on the Nasdaq SmallCap Market set forth in the Nasdaq Marketplace Rules.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. In Distribution Pact February 06, 2001
Calypte Biomedical Corp. announced that beginning this month, Organon Teknika Corporation, a provider of in vitro diagnostics, will distribute worldwide an HIV-1 Western Blot serum (blood) assay manufactured by Calypte Biomedical. Organon Teknika will distribute the test non-exclusively under Calypte`s Cambridge Biotech tradename. The long-term arrangement calls for minimum monthly shipments, significantly increasing Calypte`s serum Western Blot sales volume.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. Alameda Manufacturing Facility Approved by FDA: Alameda Facility Will Allow Increased Production of HIV-1 Antibody Urine Test January 22, 2001
Calypte Biomedical Corp. announced that it has been granted "pre-market approval" by the U.S. Food and Drug Administration (FDA) for the production, effective immediately, of the Company`s HIV-1 Urine EIA product in its manufacturing plant in Alameda, California. The facility, which is equipped with updated manufacturing technology and is larger than Calypte`s current plant in Berkeley, will significantly increase the Company`s production and distribution capabilities.
--------------------------------------------------------------------------------
International Studies Demonstrate Calypte Biomedical Corp.`s Modified HIV-1 Antibody Urine Test Competitive With Serum Testing December 20, 2000
Calypte Biomedical Corp. announced the results of two independent, international studies that examined the accuracy of the Company`s modified HIV-1 antibody urine test. Results of both studies of Calypte`s test demonstrated high concordance with serum (blood) testing, which has long been held to be the gold standard in HIV testing.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. New California Manufacturing Facility Gains State Approval - Company Expands Distribution Into Developing Countries December 20, 2000
Calypte Biomedical Corp. announced that its new manufacturing plant, based in Alameda, has received a Manufacturing License from the California Department of Health Services Food and Drug Branch. The California manufacturing license permits Calypte to manufacture its modified assay for worldwide export from its Alameda facility.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. and Becton, Dickinson and Company Announce New One-stop Testing Service December 04, 2000
Calypte Biomedical Corp. announced a joint promotional effort together with BD, whereby the companies are to co-promote the Sentinel family of testing services for urine-based testing for human immunodeficiency virus (HIV), chlamydia, and gonorrhea.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. Biomed, Osborn Science In Development Pact November 02, 2000
Calypte Biomedical Corp. announced that it is collaborating with the Osborn Scientific Group to develop two urine-based rapid HIV antibody tests. Once the assays are completed and have received regulatory clearance, Calypte and Osborn expect the products to be the first urine-based rapid HIV antibody tests.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test... August 24, 2000
Calypte Biomedical Corp. announced that its HIV-1 antibody urine test has been approved by the State Drug Administration of the People`s Republic of China, making it the only urine-based HIV-1 test approved for distribution within China. Calypte`s HIV urine test offers significant advantages over traditional HIV blood tests because unlike blood, no medical training is required to collect urine samples. In addition, the safety of both the patient and healthcare personnel are enhanced because the urine of HIV-infected people does not appear to harbor the infectious virus itself - only the harmless antibody that signifies prior exposure to HIV.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa. August 09, 2000
Calypte Biomedical Corp. announced the expansion of its innovative mobile HIV-1 antibody urine testing program from South Africa to 41 countries in sub-Saharan Africa.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer. June 13, 2000
Calypte Biomedical Corp. announced that David Collins has replaced William Boeger as Chairman and Nancy Katz was appointed Chief Executive Officer.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to... June 12, 2000
Calypte Biomedical Corp. announced it has partnered with the Chinese National Center for AIDS Prevention and Control (NCAIDS) through Beijing HuaAi Science and Technology Development Co. Ltd. to distribute the first HIV-1 antibody urine test within the People`s Republic of China. Once approved by the State Drug Administration of China (SDA), Calypte`s test will be the only urine-based HIV-1 test distributed within the People`s Republic of China. Calypte`s application has been submitted to the SDA and is currently in process, with approval expected by the end of 2000.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge... June 06, 2000
Calypte Biomedical Corp. announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. American Edge has partnered with African Medical Solutions, a South African company formed specifically to market Calypte`s products in that country.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products... May 11, 2000
Calypte Biomedical Corp. announced that it has entered into an exclusive distribution agreement with privately held Biobras S.A. of Brazil to distribute its HIV urine-based testing products throughout Brazil.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and... May 10, 2000
Calypte Biomedical Corp. announced that its Sentinel testing service, the first and only urine-based testing service dedicated exclusively to the detection of exposure to HIV-1, chlamydia, and gonorrhea sexually transmitted diseases (STDs), is now available throughout the United States. The service offers healthcare providers and patients a new fast, affordable and painless testing method for STDs. Calypte is developing a Sentinel testing service web site that will enable medical professionals and authorized institutions to order testing services directly over the Internet. The site is expected to be operational by May 12, 2000.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named... March 09, 2000
Calypte Biomedical Corp. announced that Dr. Howard Urnovitz, Calypte`s Founder and Chief Scientific Officer, and William Boeger, Calypte`s Chairman, have established a new commercial company, named Chronix Biomedical, that will focus on novel ways to detect aberrant genes in individuals with chronic diseases. Chronix will be financed independently of Calypte, but Calypte will retain rights to any urine diagnostic tests that result from its research efforts. Both Dr. Urnovitz and Mr. Boeger will maintain their current positions at Calypte.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new... January 24, 2000
Calypte Biomedical Corp. announced that it has entered into a collaboration with Wampole Laboratories, a division of Carter Wallace, Inc., and Clinical Reference Laboratory (CRL) to launch a new national urine-based testing service for HIV-1 antibody, chlamydia, and gonorrhea. The new service, called Sentinel, is a painless, non-invasive, urine-based sampling method designed to identify HIV-1 antibody and the chlamydia and gonorrhea sexually transmitted diseases (STDs).
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1)... November 19, 1999
Calypte Biomedical Corp. announced that the United States Food and Drug Administration approved a Day Assay license supplement to its "Cambridge Biotech" Human Immunodeficiency Virus Type 1 (HIV-1) Western Blot test.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the... September 16, 1999
Calypte Biomedical Corp. announced that it has signed a definitive distribution agreement that will give Carter-Wallace, Inc. the exclusive United States sales and marketing rights for the Company`s HIV products in the hospital, public health and reference lab markets. Terms were not announced.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive... August 11, 1999
Calypte Biomedical Corp. announced that it has selected four new distributors for its urine HIV-1 screening EIA and Western blot supplemental tests. Together, the distributors will have exclusive distribution rights in 13 countries throughout the Middle East, Eastern Europe and Asia. Combined, the distribution agreements call for minimum purchases of 670,000 screening tests and more than 8, 000 Western blot supplemental tests.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The... May 14, 1999
Calypte Biomedical Corp. announced that one of its newly acquired operating units, located in Rockville, Maryland, received a warning letter from the United States Food and Drug Administration. The warning letter was based upon an inspection of the Rockville manufacturing facility, which cited a number of significant observations. The facility was owned and operated at the time of the inspection by Cambridge Biotech Corp.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte... April 12, 1999
Calypte Biomedical Corp. and Carter-Wallace, Inc. announced that they have signed a letter of intent that will give Carter-Wallace the exclusive United States sales and marketing rights for Calypte Biomedical`s HIV products in the hospital, public health and reference lab markets.
--------------------------------------------------------------------------------
The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care... March 11, 1999
The Chinese National Center for AIDS Prevention and Control announced that it has selected Calypte Biomedical Corp.`s non-invasive urine HIV test for wide-scale use within the Chinese health-care system.
--------------------------------------------------------------------------------
Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients. February 25, 1999
Calypte Biomedical Corp. announced that its affiliated therapeutic Company, Pepgen Corp., will begin Phase I clinical trials of its oral interferon, Interferon Tau, in multiple sclerosis patients.
---
Quelle: steht oben
MfG
andy

[Saftladen]

wehe nicht !!!!!

[Forum]

Bevor investiert wird, solltet Ihr dieses in Eure Entscheidung einbeziehen !


Calypte Biomedical Notified of Potential Nasdaq Delisting


ALAMEDA, Calif., May 16, 2001 (BUSINESS WIRE) -- Calypte Biomedical Corporation
(Nasdaq: CALY) today announced that it was notified by Nasdaq that the Nasdaq
staff had reached a determination to delist Calypte`s common stock from the
Nasdaq SmallCap Market. Nasdaq`s decision to delist Calypte`s common stock was
based on Nasdaq Marketplace Rule 4310(c)(2)(B) and results from Calypte`s
failure to meet the three criteria relating to net assets, market capitalization
or net income.

Calypte has requested an oral hearing to review Nasdaq`s determination. The
hearing request stays the delisting of Calypte`s common stock, which otherwise
would have occurred on May 21, 2001, pending the decision of a Nasdaq Listing
Qualifications Panel. There can be no assurance that the decision of the Nasdaq
Listing Qualifications Panel will be favorable to Calypte. If Calypte`s common
stock is delisted following the hearing, the Company`s shares would likely trade
over the counter. Additionally, the Company`s continued ability to use its
equity line of financing facility is dependent upon its continued listing on the
Nasdaq SmallCap Market and any outstanding balance on its 6% convertible
debenture would become due and payable should the delisting occur.

Calypte`s President, CEO and CFO, Nancy Katz, stated, "We previously announced
this possible action by Nasdaq a month ago, and this determination letter from
the Nasdaq staff is one more step in the delisting process. While there can be
no assurance that the Listing Qualifications Panel will grant the company`s
request for continued listing on the Nasdaq National Market, we will continue to
pursue all available means to maintain this listing in concert with our active
search for strategic opportunities including investment in the Company, a merger
or other comparable transaction, the sale of certain of our assets or a
financial restructuring to sustain our operations. While some of these
opportunities are promising, we do not have any agreements in place."

Calypte Biomedical Corporation (Nasdaq: CALY) headquartered in Alameda,
California, is a public healthcare company dedicated to the development and
commercialization of urine-based diagnostic products and services for Human
Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other
infectious diseases. Calypte`s tests include the screening EIA and supplemental
Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be
used on urine samples. The company believes that accurate, non-invasive
urine-based testing methods for HIV and other infectious diseases may make
important contributions to public health by helping to foster an environment in
which testing may be done safely, economically, and painlessly. Calypte sells
its products in over 40 countries worldwide through international distributors
and strategic partners.

Statements in this press release that are not historical facts are
forward-looking statements, including statements regarding the outcome of a
Nasdaq hearing on delisting. Such statements reflect management`s current views,
are based on certain assumptions and involve risks and uncertainties. Actual
results, events, or performance may differ materially from the above
forward-looking statements due to a number of important factors, and will be
dependent upon a variety of factors, including, but not limited to our ability
to obtain additional financing that will allow us to continue our current and
future operations, our ability to draw down funds under our existing equity line
of credit and debenture agreements and whether demand for our product in
domestic and international markets will continue to expand. The Company
undertakes no obligation to publicly update these forward-looking statements to
reflect events or circumstances that occur after the date hereof or to reflect
any change in the company`s expectations with regard to these forward-looking
statements or the occurrence of unanticipated events. Factors that may impact
the Company`s success are more fully disclosed in the Company`s most recent
public filings with the U.S. Securities and Exchange Commission, including the
periodic report on Form 10-K for the year ended December 31, 2000 and its Form
10-Q for the quarter ended March 31, 2001.


CONTACT: Calypte Biomedical Corporation, Alameda
Nancy Katz, 510/749-5100
President, CEO and CFO

URL: http://www.businesswire.com
Today`s News On The Net - Business Wire`s full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2001 Business Wire. All rights reserved.



KEYWORD: CALIFORNIA
INDUSTRY KEYWORD: BIOTECHNOLOGY
MEDICAL
DEVICES

[DieNEUE]

die Info ist:
Asbach Uralt
"Schöne Augenblicke brauchen wenig Worte"
cu
DN

[STOCKLORD]

NACHBÖRSLICH 20% MINUS!!

[@andy@spazy@]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[DieNEUE]

Wo hast Du das her ?
Island.com zeigt nichts an und News gibt es nicht.
DN

[Domasle]

20% minus Stocklord verpiss dich weis nicht nach wie vor 0,25 was willst du ?

[DieNEUE]

Das führt zu einem Prozeß
Die IP Daten wurden gesichert
Sollte sich herausstellen dass es keine 20% Minus nachbörslich gibt, dann kommt eine strafrechtliche Verfolgung.
Grund Kursmanipulation in Form von Lügen um den Kurs zu drücken.

Spekulationen sind o.k.
Annahmen sind o.k.
Kursziele nennen sind o.k.

Aber Lügen in Form von BASHEN ist NICHT o.k.

DN

[smarty7]

@Bulle Andy
Danke erst mal für die Informationen zu CALY. Mein Eindruck ist, daß die Chancen bei diesem Wert größer sind als die Risiken. Alles negative scheint schon eingespeist!!

[DieNEUE]

http://quotes.nasdaq.com/quote.dll?page=afterhours&mode=fram…

After Hours Trade Reporting
Tuesday June 5 After Hours Most Active
After Hours
Last: N/A After Hours
Best Bid: $0.24 After Hours
High: N/A
After Hours
Volume: N/A After Hours
Best Ask: $0.27 After Hours
Low: N/A

Aber nun seine Seite bei CNBC zeigt tatsächlich 19,2 % an

Was soll das ?

STOCKLORD hast Glück gehabt.
MfG
DN

[benjamin1896]

Hi,

nur zur info, Calypte eröffnet unverändert!

CALYPTE BIOMEDICAL Nasdaq 131722100 0,25 +0,00 +0,00% 7.450,00 15:31/06.06

Ich bin jetzt übrigens auch drin (wenn auch nur mit einen kleinen Betrag). Ich sehe viel Phantasie nach oben.

Gruß an alle

[benjamin1896]

Hi,

nur zur info, Calypte eröffnet unverändert!

CALYPTE BIOMEDICAL Nasdaq 131722100 0,25 +0,00 +0,00% 7.450,00 15:31/06.06

Ich bin jetzt übrigens auch drin (wenn auch nur mit einen kleinen Betrag). Ich sehe viel Phantasie nach oben.

Gruß an alle

[DieNEUE]

So kann man sich auf die vorbörslichen Kurse verlassen
Gleich Null
MfG
DN
P.S.
Sehe mal Berlin -Staune Mann und Söhne-
Verkauf Orders
Limit Überhang
0.58 500

Da will einer zu 0,58 E verkaufen.
FrechDAX

[orpheo]

andy

es gibt keine shortsqueezes in CALY
zZ 130K shorts outstanding!

bei aktien unter 5$ kann nicht mehr geshortet werden.

die hüpfer im kurs sind oft fakes, basierend auf gerüchten.

was nicht heissen soll, dass ich in CALY kein potential sehe

gruss
o.

[rabenplatz]

hab grad mal kurz über google infos gelesen.
im moment läuft was mit nasy-delisting.
mal abwarten?????

[DieNEUE]

Doch mann kann shorten.
Ich kann sogar OTC Werte shorten
Frage mal hier nach.
www.trading-house.net

cu
DN-Die Freundin v. A -zwinker-

[Geldcasher]

Servas
Andy

gratuliere zur CALY = die geht heute durch die Decke

gruß
Geldcasher

[Alpeninvestor]

Was ist da los???

Realtime USA: 0.37$ (+48%)

After Hour gingen die soger bis 0,43$

Da muß doch irgenwas kommen!!!

mfg AIV

[thomas15]

@BulleAndy
nochmals danke für den Supertipp...........

[stoss]

bid 0,42 ask 0,47
ist doch super
bin bei 0,34 gestern rein

[lisafeuerstein]

wann soll den das DELISTING entschieden werden?

[lisafeuerstein]

HAAAAAAALOOOOOOOOOO

ist hier keiner mehr..??

alle schon die gewinne realisiert und auf nimmer wiedersehen??

[nasdaqhans]

So ist es!!!!!!
Gewinne realisieren und tschüss.......
Na wo ist denn Andi??????
Hat er sich bereits einen neuen Namen zugelegt???
cu
Nasdaq

Ps.ie Firma steht am Rande der "Pleite",schaut euch die Bilanzen an.Hier hilft nur noch eine fette Geldspritze.

[thomas15]

abwarten und Tee trinken........

[lisafeuerstein]

also die amis stellen derzeit 0,32 zu 0,33. Kurs derzeit 0,32 bei 255 tradings mit einem volumen von 0,5 mio

0,32USD = ca. 0,37€ - also da, wo die aktie herkommt....

schade eigentlich....

[nasdaqhans]

Wer sagt dir denn,daß es die Amis sind??????
Gruß
Nasdaq

[DieNEUE]

Hallo
Danke für das Lob
ich war heute im Kino
Pearl Habor
Geiler Film absolut sehenwert.
Zu CALY
Da ist was im Busch, die Umsätze ziehen stark an
Über 1$ ist das Delisting vom Tisch.
Dann kommt der zweite Hype
Nasdaq Hans
Leider wurde BulleAndy aus unbekannten Gründen gesperrt.
Egal
CU
Die Freundin von Andy -zwinker-

[nasdaqhans]

Hi "Die Neue",
dann richte "BulleAndy" Grüße von mir aus.Großes Kompliment von mir,hat er Klasse gemacht!Man lernt immer hinzu.Er sollte sich in ruhigeres Fahrwasser begeben,da kann man auch gut Kohle machen.Eben auf die feine Art.....
cu
Nasdaq

[DieNEUE]

Sage ich Ihm, aber so kennen wie Ihn

MfG
DN

P.S.
Wer etwas über AIDS erfahren will und warum Andy so positiv bei CALY gestimmt ist, der sollte hier mal etwas lesen.
http://www.aidshilfe.de/

Die Welt kann CALY nicht einfach fallen lassen.
Schon aus humanitären Gründen nicht.
Der HIV Test von CALY wird welteweit benötigt und das CASH verbrennen ist doch logisch.
Die Mediziner arbeiten nicht umsonst.
Wer könnte CALY und zu welchem Kurs übernehmen ?
Das ist die eine Million Dollar Frage.

[DieNEUE]

http://allafrica.com/stories/200007140116.html
Calypte To Distribute Its HIV-1 Urine Test In South Africa

Calypte Biomedical Corporation

DOCUMENT
July 14, 2000
Posted to the web July 14, 2000

Alameda, Calif.

Calypte Biomedical Corporation (NASDAQ: CALY) announced today the appointment of American Edge Medical Company as the exclusive distributor of its urine HIV-1 antibody testing products in South Africa. Miami- based American Edge has partnered with African Medical Solutions (AMS), a South African company formed specifically to market Calypte`s products in that country.

It is estimated that 10 percent of South Africa`s 43 million people are infected with HIV or AIDS. The global HIV/AIDS epidemic is so far reaching that the Clinton administration has for the first time formally declared it a threat to United States national security. A crucial first step to stemming the deadly spread of HIV in South Africa is testing and education. However, major challenges to an effective widespread testing effort include the vast size of the country, remote populations, poor infrastructure and relatively few trained healthcare providers.

Significant advantages of Calypte`s urine HIV-1 antibody tests are that unlike blood, urine samples can be obtained by non-medical professionals, have a long shelf life, are not considered hazardous and require no refrigeration. An additional advantage of urine testing over blood is that urine does not appear to harbor the infectious virus itself and according to the National Institutes of Health Fact Sheet on HIV Infection and AIDS, there is no evidence that HIV is spread through urine.

"Urine-based testing provides a safer and more convenient means of testing than traditional blood serum testing - a factor that is pertinent to sub-Saharan Africa where 60 percent of the world`s HIV cases are found," said Professor Anthony E. Bunn, PhD, Programme Director of the Technology &Business Development Group of the South African Medical Research Council. In a novel distribution approach, AMS is creating its own mobile and containerized HIV testing and education program. Using shipping containers custom-engineered as "container clinics" and motor vehicles custom modified into state-of-the-art "mobile clinics," AMS staff will fan out across South Africa to bring HIV education and testing directly to the townships and remote areas of the country. "Through this unique blend of African entrepreneurship and American technology, much can be done to combat the spread of HIV in Africa," said Dr. Bunn.

"AMS stands apart from most sales and distribution firms because our mission includes helping as many South Africans as possible learn their HIV status," said Gavin Walton, Co-Director of African Medical Solutions. Our goal is to test, counsel and educate people throughout South Africa. With the creation of our fleet of mobile clinics, we`ll knock down the boundaries that currently thwart an effective effort," Walton said.

"Clearly this situation calls for immediate attention, which is why we are so enthusiastic about our partnership with American Edge and African Medical Solutions," said Nancy E. Katz, President of Calypte. "Their vision of creating an infrastructure to help combat South Africa`s HIV problem holds promise for a broad-based effort against this devastating disease."

The South African Medical Research Council and AMS have jointly approached the European Union regarding pilot financing for the container clinics. AMS expects to eventually field a total of 1000 container clinics and 450 mobile clinics, with the first units deployed by September 2000. Medical professionals and the media will have an opportunity to see firsthand one of AMS`s "container clinics" at the 13th International AIDS Conference to be held in Durban, South Africa from July 9-14, 2000.

Calypte Biomedical Corporation (NASDAQ: CALY) is a health care company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other chronic illnesses. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-licensed HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non invasive urine-based testing methods for HIV and other chronic diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly.

Statements in this press release that are not historical facts are forward- looking statements, including statements regarding market adoption of the HIV-1 urine testing products and the serum Western Blot test and statements regarding marketing and distribution arrangements and plans.

Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including the Company`s ability, directly or through third parties, to successfully manufacture and market the HIV-1 urine testing products and the serum Western Blot test and the ability of the Company to continue to finance its operations and to enter into distribution and marketing arrangements. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events. Factors that may impact the Company`s success are more fully disclosed in the Company`s most recent periodic report on Form 10-Q.

1265 Harbor Bay Parkway Alameda, CA 94502

Contacts: Nancy Katz, President www.calypte.com or David Collins, CEO 510- 749-5100

[DieNEUE]

http://www.aegis.org/news/bw/2000/BW000806.html
[/B]Calypte`s HIV-1 Urine Test Approved for Use in People`s Republic of China

Business Wire - August 24, 2000


--------------------------------------------------------------------------------
ALAMEDA, Calif.--(BUSINESS WIRE)--Aug. 24, 2000-- Calypte Biomedical Corporation (Nasdaq: CALY) announced today that its HIV-1 antibody urine test has been approved by the State Drug Administration (SDA) of the People`s Republic of China (PRC), making it the only urine-based HIV-1 test approved for distribution within China. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS), half a million Chinese citizens are currently infected with the HIV virus. Left unchecked, officials of the Chinese National Center for AIDS Prevention and Control (NCAIDS) estimate that the total number of HIV infections in China could reach 10 million before 2010. NCAIDS is a national research center run by the Chinese Academy of Preventive Medicine (CAPM), which is under the leadership of the Chinese Ministry of Health.
In June of this year, Calypte announced that it had partnered with NCAIDS through Beijing HuaAi Science and Technology Development Co. Ltd. to distribute Calypte`s HIV-1 urine test within the PRC. Beijing HuaAi has contracted with Guizhou Zheng Xin Industry Company, Ltd. to handle sales and distribution logistics through Guizhou Zheng Xin`s 180-person dedicated sales force and its 26 offices throughout the PRC. Guizhou Zheng Xin will begin training its sales and technical staff in September to support the distribution of the Calypte test. NCAIDS and CAPM have guaranteed the terms of the contract.

"The approval of the Calypte HIV urine test in China is an important milestone in expanding the reach of Calypte`s urine-based product internationally," said Nancy E. Katz, President and CEO of Calypte. "With the number of HIV-infected people in China growing at a rate of 30 percent each year and the reported difficulty in obtaining blood samples from a substantial percentage of those in high risk groups, there is significant unmet need for an effective, easy-to-use alternative. Now that Calypte`s urine-based test has been approved for distribution throughout China, we look forward to addressing that demand. We currently plan to begin shipping tests in the fourth quarter of this year."

A key to slowing the spread of HIV lies in a widespread screening program. However, according to Xiwen Zheng, MD, Executive Deputy Director of NCAIDS, during recent HIV detection efforts in China, roughly 30 percent of people to be tested were unwilling to have their blood drawn for traditional HIV tests.

"The SDA approval is very important because Calypte`s urine-based HIV test is ideal for our testing programs - this action will pave the way for us to launch major screening efforts," said Dr. Yunzhen Cao, Deputy Director of NCAIDS and Director of the Department of Clinical Virology. "We plan to have our regional laboratories fully trained in the use of this new technology before the end of September." Dr. Cao helped develop Calypte`s HIV-1 urine enzyme immunoassay test and is a co-holder of the urine HIV antibody patent, along with Alvin Friedman-Kien, MD. They were the first to report the detection of antibodies to HIV in urine.

PRC government figures indicate that intravenous drug users account for 70 percent of the HIV-positive population in the PRC, a rate ten times higher than that of patients infected by sexual transmission. Those figures are a marked contrast to most of the rest of the world, where the majority of HIV transmissions are caused by unsafe sexual relations.

"There are approximately 10 million drug users in China, and we have found that it can be difficult to collect blood samples from them," said Dr. Cao. "Providing drug users with the option of urine testing could significantly increase the number of people who get tested for HIV."

Another potential reason for the accelerating spread of HIV within the PRC is the dangerous practice of selling blood on the black market. Since blood collection in this market is usually conducted using unsterile methods, donors are often exposed to an array of blood-borne diseases. Although outlawed by China in 1998, recent media reports claim that the practice remains fairly common among China`s poorest citizens. In addition, a report from UNAIDS indicates that only five percent of estimated HIV/AIDS cases are actually reported, further compounding the danger of illegal blood sales.

Calypte`s HIV urine test offers significant advantages over traditional HIV blood tests because unlike blood, no medical training is required to collect urine samples. In addition, the safety of both the patient and healthcare personnel are enhanced because the urine of HIV-infected people does not appear to harbor the infectious virus itself - only the harmless antibody that signifies prior exposure to HIV. According to information provided by the U.S. National Institutes of Health, there is no evidence that HIV is spread through urine. Urine sampling is also highly flexible and can be employed in a wide range of settings because, unlike blood, urine is very stable and requires no refrigeration.

Calypte Biomedical Corporation (NASDAQ: CALY) is a health care company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other chronic illnesses. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-licensed HIV-1 antibody tests that can be used on urine samples. The Company believes that accurate, non-invasive urine-based testing methods for HIV and other chronic diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding market adoption of the HIV-1 urine testing products and the serum Western Blot test and statements regarding marketing and distribution arrangements and plans. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including the Company`s ability, directly or through third parties, to successfully manufacture and market the HIV-1 urine testing products and the serum Western Blot test and the ability of the Company to continue to finance its operations and to enter into distribution and marketing arrangements. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect the occurrence of unanticipated events. Factors which may impact the Company`s success are more fully disclosed in the Company`s most recent periodic reports on Forms 10-K and 10Q.

CONTACT: Calypte Biomedical Nancy Katz, 510/749-5100 or Ketchum James Larkin, 415/984-2285
000824
BW000806

[DieNEUE]

Heute wieder 30% plus
Frankfurt sogar bis 0,60 E
Na das ist doch mal etwas Gutes.
MfG
DN

[thomas15]

@DieNeue

morgen 30% wäre auch nicht schlecht........

[thomas15]

nachbörslich bei 45 cent......

[DieNEUE]

THOMAS15
Wo siehst Du die ,45$
Island.com ?
MfG
DN

[lutzeggi]

oder auch
nasdaq.com
dann caly eibgeben
dann caly klicken
dann extended trading

da steht denn 0.45 $ ! (freu)

mfg lutz

[lutzeggi]

wir siehts denn morgen zum nachkaufen aus ?
lieber warten was der tag vor usa eröffnung bringt
oder gleich zur (wohl recht hohen D eröffnung..)
einsteigen ?

[DieNEUE]

lutzeggi
IMMER gemäß Cost Average Effekt
In kleinen Stückkäufen zum MARKT BESTEN PREIS *KAUFEN*

NIE NIE ALLES **CASH*** VERBALLERN

Schön stückweise einsammeln.
MfG
DN

[asskicker]

CALY nachbörslich 0,46$ !! YEAH !!

http://htmlgritch.island.com/SERVICE/QUOTE?STOCK=caly

Unter 0,60€ wird hier gar nichts gehen heute !!

[ac666]

@DieNEUE Dankeschön für Deine Beiträge

Ich will sie hier ´mal kurz anhängen:

1.
Kann sich Afrika und China überhaupt solch einen Aidstest leisten? Ist er bezahlbar? In Afrika sterben die Menschen viel zu früh an Aids, da sie sich nicht einmal die einfachsten Mittel zur Linderung leisten können. Vielleicht ist es bei dem Test das Gleiche.
Antwort:Lese mal bitte die alten News und folgenden Info:
Quelle:http://www.rethinkingaids.de/afrika/freivon.htm
Ebenfalls im Dezember gab die Weltbank zusammen mit dem IWF und einigen Gläubigerstaaten einen Schuldenerlaß bekannt: Für 22 Länder, unter ihnen viele in Afrika, stehen 42 Milliarden US-$ zur Verfügung, weitere 28 Milliarden US-$ sollen entsprechend vergeben werden. Gekoppelt ist der Erlaß an „Armutsbekämpfung" (der neue Name für die alte Strukturanpassung), deren integraler Bestandteil inzwischen AIDS geworden ist. Das nennt BMZ-Ministerin Wieczorek-Zeul [40] „eine frohe Botschaft für Millionen von Menschen", während es in UNAIDSpeak treffender unter „mainstreaming AIDS" läuft.

2.
Gibt es konkurrerenz-Produkte von geldmäßig potenteren Firmen?
Antwort:NEIN

3.
Ist die Analysemethode genau so treffsicher wie bei der Blutabnahme? Sonst wäre sie sicherlich nicht gut zu verkaufen.
Antwort:JA zu 99,7%: Hier ein Tesxt:
Das Unternehmen hat eine eigene Technologie entwickelt, mit Hilfe derer ein Test entwickelt wurde, der das Vorhandensein von HIV-Antikörpern im Urin mit einer Genauigkeit von 99,7% nachweisen kann.

4.
Warum ist der Kurs so im Keller, obwohl sich das Produkt so gut anhört. Da sind ganz andere Firmen ausgebrochen. Gerade bei diesem Biotechnolgie Hype ist das sehr verwunderlich.
Wo ist der Haken.
Antwort:
CALY hat die Löhne für die Entwicklung aus eigener Kraft zahlen müssen. Die fetten Umsätzte aus den Afrika und China Verträgen kommen erst jetzt und weiterhin bekam CALY von der NASDA ein Standardschreiben da CALY unter 1$ steht-Übriegens auch 200 andere Firmen haben diesen Brief bekommen.
Im N-TV habe ich einen Bericht gesehen, dass die einzelnen Firmen noch mit der NASDAQ persönlich verhandeln können und eine Zeitvereinbarung treffen können, um die UMSÄTZE,MARKT KAP. und Gewinne neu zu präsentieren.
( übriegens jeder Anstieg ist positiv für uns da die Markt Kap. steigt)

[Kim-Marwin]

Es ist richtig, dass das Delisting vorerst umgangen werden kann, wenn das Unetrnehmen eine schlüssige Konzeption über den weiteren positiven Geschäftsablauf vorlegen kann und dementsprechend natürlich ihre eigene Finanzierung positiv darstellen kann. Siehe hierzu Intasys, haben es im Dez/Jan auch geschafft, das Delisting auf 6 Monate vorerst zu stoppen.
Gruß